AHCO

Adapthealth Corp

Add to Watchlist

Advanced Chart

9.330

+0.14(1.523%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.420

Open

9.270

VWAP

9.27

Vol

906.12K

Mkt Cap

1.26B

Low

9.160

Amount

8.40M

EV/EBITDA(TTM)

4.71

Total Shares

133.20M

3.03B

EV/OCF(TTM)

5.49

P/S(TTM)

0.39

AdaptHealth Corp. is a provider of patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home. Its product and service offerings include sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea; medical devices and supplies to patients for the treatment of diabetes, including continuous glucose monitors and insulin pumps; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. It operates in 50 states through its network of over 670 locations in 47 states.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

799.47M

-0.79%

0.224

+1.78%

844.73M

-1.39%

0.415

-1.08%

812.70M

+4.48%

0.137

+472.42%

Estimates Revision

The market is revising Downward the revenue expectations for AdaptHealth Corp. (AHCO) for FY2025, with the revenue forecasts being adjusted by -0.35% over the past three months. During the same period, the stock price has changed by 2.41%.

Revenue Estimates for FY2025

Revise Downward

-0.35%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.16%

In Past 3 Month

Stock Price

Go Up

+2.41%

In Past 3 Month

5 Analyst Rating

27.33% Upside

Wall Street analysts forecast AHCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AHCO is 11.88 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

27.33% Upside

Current: 9.330

Low

10.00

Averages

11.88

High

14.00

27.33% Upside

Current: 9.330

Low

10.00

Averages

11.88

High

14.00

Truist

Buy

downgrade

$14 -> $13

2025-05-12

Reason

Truist

Price Target

$14 -> $13

2025-05-12

downgrade

Buy

Reason

Truist lowered the firm's price target on AdaptHealth to $13 from $14 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.

Baird

Eric Coldwell

Buy

Maintains

$14 → $16

2025-02-27

Reason

Baird

Eric Coldwell

Price Target

$14 → $16

2025-02-27

Maintains

Buy

Reason

Baird raised the firm's price target on AdaptHealth to $16 from $14 and keeps an Outperform rating on the shares. The firm said they posted good Q4 results and a positive 2025 outlook.

Truist Securities

David Macdonald

Strong Buy

Maintains

$12 → $14

2025-02-26

Reason

Truist Securities

David Macdonald

Price Target

$12 → $14

2025-02-26

Maintains

Strong Buy

Reason

RBC Capital

Ben Hendrix

Buy

Maintains

$11 → $14

2025-02-26

Reason

RBC Capital

Ben Hendrix

Price Target

$11 → $14

2025-02-26

Maintains

Buy

Reason

RBC Capital raised the firm's price target on AdaptHealth to $14 from $11 and keeps an Outperform rating on the shares after its Q4 earnings beat. The company saw a strong finish to 2024 and gave solid initial guidance, the analyst tells investors in a research note. Early signs that the strategic overhaul to the Diabetes business announced last quarter may be taking hold, the firm adds.

Canaccord Genuity

Richard Close

Strong Buy

Maintains

$13 → $14

2025-02-26

Reason

Canaccord Genuity

Richard Close

Price Target

$13 → $14

2025-02-26

Maintains

Strong Buy

Reason

Canaccord analyst Richard Close raised the firm's price target on AdaptHealth to $14 from $13 and keeps a Buy rating on the shares. The firm said 4Q was a step forward in rebuilding investor confidence for Adapt as results showed revenue upside and 2025 guidance that has revenue and adj-EBITDA ranges bracketing both Canaccord and consensus prior estimates, and a respectable FCF range of $180-$220 million.

UBS

Whit Mayo

Strong Buy

Maintains

$12 → $11

2025-02-13

Reason

UBS

Whit Mayo

Price Target

$12 → $11

2025-02-13

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Adapthealth Corp (AHCO.O) is 9.43, compared to its 5-year average forward P/E of 15.80. For a more detailed relative valuation and DCF analysis to assess Adapthealth Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

15.80

Current PE

9.43

Overvalued PE

22.65

Undervalued PE

8.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

6.28

Current EV/EBITDA

4.50

Overvalued EV/EBITDA

7.60

Undervalued EV/EBITDA

4.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

0.74

Current PS

0.37

Overvalued PS

1.11

Undervalued PS

0.36

Financials

Annual

Quarterly

FY2025Q2

YoY :

-0.70%

800.37M

Total Revenue

FY2025Q2

YoY :

-16.18%

56.83M

Operating Profit

FY2025Q2

YoY :

-22.91%

15.83M

Net Income after Tax

FY2025Q2

YoY :

-23.08%

0.10

EPS - Diluted

FY2025Q2

YoY :

-37.17%

73.33M

Free Cash Flow

FY2025Q2

YoY :

+25.87%

18.05

Gross Profit Margin - %

FY2025Q2

YoY :

-22.35%

1.98

Net Margin - %

FY2025Q2

3.92

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

327.3K

USD

0-12

Months

281.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1321.21% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

969.4K

Volume

Months

6-9

68.2K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

327.3K

USD

0-12

Months

281.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AHCO News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

09:30:52

AdaptHealth partners with national healthcare system for home medical equipment

2025-08-05

07:59:51

AdaptHealth narrows FY25 revenue view to $3.18B-$3.26B from $3.15B-$3.29B

2025-08-05

07:56:55

AdaptHealth reports Q2 EPS 10c, consensus 16c

News

3.0

08-04Yahoo Finance

AdaptHealth (AHCO) To Report Earnings Tomorrow: Here Is What To Expect

7.0

07-02Globenewswire

Important Notice to Long-Term Shareholders of AdaptHealth Corp. (NASDAQ: AHCO); CorMedix Inc. (NASDAQ: CRMD); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law Office is Investigating Claims on Your Behalf as Key Developments Occur in Underlying Class Actions

9.5

06-27Benzinga

Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session